EMA Recommends Seven Medicines for Approval in October
The recommended medicines include treatments for Duchenne muscular dystrophy, relapsed or refractory multiple myeloma, hyperargininemia, invasive candidiasis, menopause symptoms, and diagnostic medicines for characterizing lesions.
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
The European Medicines Agency (EMA) announced on Oct. 13, 2023 that the agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended seven new medicines for the treatment of a variety of conditions, including Duchenne muscular dystrophy, relapsed or refractory multiple myeloma, hyperargininemia, invasive candidiasis,menopause symptoms, and diagnostic medicines for characterizing lesions. EMA also announced two withdrawn marketing applications—for Jivadco and Sugammadex Lorien—and reexamination requests for Translarna and Blenrep. A review of the benefits and risks of Ocaliva (obeticholic acid), which treats adults with primary biliary cholangitis, was also initiated.
Among the positive opinions granted by CHMP is a treatment for Duchenne muscular dystrophy, Agamree (vamorolone), which is a genetic disorder with progressive loss of muscle function. Elrexfio (elranatamab) was approved for the treatment of adult patients with relapsed or refractory multiple myeloma, a rare cancer of the bone marrow. A positive opinion under exceptional circumstances was granted to Loargys (pegzilarginase) for the treatment of a rare disease with neurological clinical signs, hyperargininemia. Rezzayo (rezafungin) was granted approval for the treatment of invasive candidiasis, a serious fungal infection caused by Candida. In addition, a treatment for moderate-to-severe hot flashes due to menopause—Veoza (fezolinetant)—was approved.
Two diagnostic medicines for the detection of central nervous system lesions—Elucirem (gadopiclenol) and Vueway—were also approved. CHMP also extended indications for Brukinsa, Imfinzi, Jemperli, Keytruda, Praluent, Prevymis, Rubraca, and Veyvondi.
Source: EMA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
